Data On Russia’s Sputnik V COVID Vaccine


Health Editor’s Note: Results of Russia’s Sputnik V COVID Vaccine Look very good.  I would take it….Carol

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

  • Denis Y Logunov, DSc  *
  • Inna V Dolzhikova, PhD *
  • Dmitry V Shcheblyakov, PhD
  • Amir I Tukhvatulin, PhD
  • Olga V Zubkova, PhD
  • Alina S Dzharullaeva, MSc
  • et al.
  • Show all authors
  • Show footnotes
Published:February 02, 2021DOI:
A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial.


We did a randomised, double-blind, placebo-controlled, phase 3 trial at 25 hospitals and polyclinics in Moscow, Russia. We included participants aged at least 18 years, with negative SARS-CoV-2 PCR and IgG and IgM tests, no infectious diseases in the 14 days before enrolment, and no other vaccinations in the 30 days before enrolment. Participants were randomly assigned (3:1) to receive vaccine or placebo, with stratification by age group. Investigators, participants, and all study staff were masked to group assignment. The vaccine was administered (0·5 mL/dose) intramuscularly in a prime-boost regimen: a 21-day interval between the first dose (rAd26) and the second dose (rAd5), both vectors carrying the gene for the full-length SARS-CoV-2 glycoprotein S. The primary outcome was the proportion of participants with PCR-confirmed COVID-19 from day 21 after receiving the first dose. All analyses excluded participants with protocol violations: the primary outcome was assessed in participants who had received two doses of vaccine or placebo, serious adverse events were assessed in all participants who had received at least one dose at the time of database lock, and rare adverse events were assessed in all participants who had received two doses and for whom all available data were verified in the case report form at the time of database lock. The trial is registered at (NCT04530396).
Read More of this Lancet Article:


We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.


  1. davor, Lots of countries will be using Sputnik V. Mexico was to import 7.4 million doses of the Russian COVID-19 vaccine Sputnik V from February and April 2021. More vaccines would be delivered in May. Russia was to sell 100 million vaccine doses to India. India was among the countries that agreed with Russia to produce Sputnik V on its territory. Indian company Hetero planned to produce over 100 million doses of the vaccine per year. Sputnik V was registered in Algeria, Argentina, Armenia, Belarus, Bolivia, Guinea, Hungary, Palestine, Paraguay, Russia, Serbia, Tunisia, Turkmenistan, United Arab Emirates, and Venezuela as of February 1, 2021.

  2. So only Lancet does it for the western-oriented mind. So many other “irrelevant” countries did not wait for Lancet validation.

Comments are closed.